Purpose of review: Metastatic or unresectable urotheliat cancer of the urinary bladder has traditionally been treated with systemic chemotherapy, which is most often platinum-based. The long-term survival data and the associated toxicities from this form of therapy have spurred continuing interest in finding novel treatment options for this malignancy. Recent findings: Recently, trials of new chemotherapy combinations, many incorporating platinum analogs or deleting platinum entirely, have been reported. None has yet been shown to be superior to cisplatin-based regimens. In addition, recent advances in imaging and laboratory technologies have provided new avenues to understand urothelial cancer behavior and prognosis. These advances provide optimism for improvements in the diagnosis, staging, and ultimately, selection of therapy for patients with urothelial cancer. Summary: This review will summarize recent developments (circa 2004) in the diagnosis and management of advanced bladder cancer.
|Original language||English (US)|
|Number of pages||8|
|Journal||Current Opinion in Urology|
|State||Published - Sep 2005|
- Epidermal growth factor receptor
- Metastatic bladder cancer
ASJC Scopus subject areas